PIPELINE

Serina Therapeutics is developing proprietary drugs to treat neurological diseases, cancer and pain. In addition, we are partnering our POZ™ platform to develop pharmaceuticals for other companies – which include antibody drug conjugates, proteins and small molecules. Our POZ drug conjugate platform is broad, customizable and versatile, and can be dosed via IV,   SC or IM routes.

PIPELINE

DRUG CANDIDATE INDICATION RESEARCH PRECLINICAL PHASE 1 PHASE 2 PHASE 3
SER-214 (rotigotine)* Parkinson’s Disease
SER-214 (rotigotine) Restless Leg Syndrome
SER-226 (buprenorphine) Post operative pain management
Addiction
SER-228 (cannabidiol)​ Refractory epilepsy
Pain
SER-232
(tetrahydrocannabinol)
CINV
Multiple indications
Multi-target, multi-toxin
Antibody Drug Conjugate
Solid tumors
(Partnered)

*SER-214 is a first-in-class drug for two major dopamine-responsive disorders. Click the blue circles above to learn more about SER-214.

PARKINSON’S DISEASE

Parkinson’s disease (PD) is a chronic, progressive neurological disorder that results from a deficiency of dopamine in a specialized region of the brain known as the substantia nigra. As many as ten million people worldwide may be affected by the disease. Current treatments for PD often need to be individually titrated in patients, often several times a day. None of these therapies deliver the drug continuously to replace the deficiency of dopamine in the brain. As a result, many of these drugs are complicated by “wearing off” and involuntary motor fluctuation known as dyskinesia.

If you are a patient with PD you and your physician can find more information on the Phase I SER-214 study by visiting ClinicalTrials.gov here, or the Michael J Fox Foundation website here.

Learn More | SER-214 Fact Sheet

APPLICATIONS OF THE POZ PLATFORM

ABILITY TO PROVIDE CONTINUOUS DRUG DELIVERY

Many drugs, for example those used to treat neurological disorders like Parkinson’s disease, pain and cancer, have narrow therapeutic ranges in which they can work safely and efficaciously. They are often dosed more frequently – resulting in large and frequent fluctuations in drug exposure. Such drugs may have to be monitored and the dose adjusted with greater frequency, and on an individual basis. These fluctuations present clinical, compliance and quality of life challenges for many patients. POZ™ technology provides greater control in drug loading, and the rate of release of attached drugs can often be more precisely controlled. Thus, drugs with narrow therapeutic windows can be designed to maintain more desirable and stable levels in the blood.

ABILITY TO TARGET CANCER WITH POZ™-POLYMERS

Increasing DAR Using Antibody Drug Conjugates

Serina has shown that POZ™ polymers can be attached to antibodies, and when those polymers are “pay-loaded” with large amounts of cytotoxic agents they can dramatically increase the drug antibody ratio (DAR). We and our partners believe that this will be particularly important when the antigen for the ADC has low cell surface expression.

For an illustration of how this is accomplished, click here.

Targeting POZ™ to Cell Surface Receptors by Small Molecules

POZ technology is uniquely suited for targeting a “payload” of toxin to specific receptors that are overexpressed on the surface of cancer cells. An example of this is the high affinity folate receptor alpha, which is expressed only on the surface of certain types of cancers.

Both of these approaches may prove to be highly advantageous for the treatment of cancer, but could also be applied to treat other diseases where the release of the attached drug needs to be site specific.